Abstract:
Inflammatory bowel diseases (IBDs), such as Crohn\'s disease (CD) and ulcerative colitis (UC), are chronic diseases of the digestive system with a multifactorial and not fully understood etiology. There is research suggesting that they may be initiated by genetic, immunological, and lifestyle factors. In turn, all of these factors play an important role in the modulation of intestinal microflora, and a significant proportion of IBD patients struggle with intestinal dysbiosis, which leads to the conclusion that intestinal microflora disorders may significantly increase the risk of developing IBD. Additionally, in IBD patients, Toll-like receptors (TLRs) produced by intestinal epithelial cells and dendritic cells treat intestinal bacterial antigens as pathogens, which causes a disruption of the immune response, resulting in the development of an inflammatory process. This may result in the occurrence of intestinal dysbiosis, which IBD patients are significantly vulnerable to. In this study, we reviewed scientific studies (in particular, systematic reviews with meta-analyses, being studies with the highest level of evidence) regarding the microflora of patients with IBD vs. the microflora in healthy people, and the use of various strains in IBD therapy.
摘要:
炎症性肠病(IBDs),如克罗恩病(CD)和溃疡性结肠炎(UC),是消化系统的慢性疾病,具有多因素且尚未完全了解病因。有研究表明,它们可能是由遗传引发的,免疫学,和生活方式因素。反过来,所有这些因素在肠道菌群的调节中起着重要作用,很大一部分IBD患者患有肠道菌群失调,由此得出的结论是肠道菌群紊乱可能显著增加IBD的发病风险。此外,在IBD患者中,肠道上皮细胞和树突状细胞产生的Toll样受体(TLRs)将肠道细菌抗原作为病原体,导致免疫反应中断,导致炎症过程的发展。这可能导致肠道菌群失调的发生,IBD患者明显易感。在这项研究中,我们回顾了科学研究(特别是,具有荟萃分析的系统评价,作为具有最高证据水平的研究)关于IBD患者的微生物区系与健康人体内的微生物,以及各种菌株在IBD治疗中的应用。